Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran

Alavian, Seyed Moayed; Lankarani, Kamran Bagheri; Aalaei‐Andabili, Seyed Hossein; Pouryasin, Ali; Daryani, Nasser Ebrahimi; Toosi, Mohsen Nassiri; Malekzadeh, Reza; Zali, Mohammad Reza; Mohraz, Mino

doi:10.5812/kowsar.1735143x.501

Cited by 5 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiviral therapy plays an important role in treating patients with HCV infection, because SVR prevents progression of fibrosis, decreases hepatic inflammation and necrosis, reduces the risk of HCC, and improves patient survival (5, 19, 20). Genotype, viral load and liver biopsy are important parameters used in selecting an antiviral therapy with the maximum chance of success (21, 22).…”

Section: Methodsmentioning

confidence: 99%

“…HCV prevalence has changed significantly world-wide, showing a decreasing trend in the developed world due to a decrease in infections among injecting drug users, the effect of harm reduction programs, and the reduced risk of transfusion-associated acute HCV. In contrast, HCV prevalence is high in undeveloped countries and high-risk groups (5). The prevalence of HCV infection in the general population is less than 1% in Iran (6, 7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

et al. 2013

View full text Add to dashboard Cite

BackgroundHCV virus (HCV) is a significant global problem with wide-ranging socio-economic impacts. Because of the high morbidity and mortality associated with end-stage liver disease, cirrhosis, and hepatocellular carcinoma (HCC), the economic burden of HCV infection is substantial.ObjectivesThis study aimed to estimate the direct medical care costs of chronic HCV infection.Patients and MethodsFor this cross-sectional study, 365 courses of HCV treatment were extracted from medical records of 284 patients being referred to Tehran HCV clinic, a clinical clinic of Baqiyatallah Research Center for Gastroenterology and Liver diseases, from 2005 to 2010. All the patients had been diagnosed with HCV. Direct medical care costs for each course of HCV treatment have been calculated based on Purchasing Power Parity Dollar (PPP$).ResultsAverage direct medical costs for the courses treated with conventional interferon plus ribavirin (INF-RBV) were 4,403 PPP$, and 20,010 PPP$ for peg-interferon plus ribavirin (PEG-RBV) courses. There was an increase of the direct costs in both courses of treatment to achieve Sustain Viral Response (SVR). The costs amounted to 10,072 PPP$ in (INF-RBV) treatment and 34,035 PPP$ in (PEG-RBV). The significant difference between the costs of these two courses of treatment is attributable to high cost of Peg-interferon. This indicates that the medication costs are the dominant costs.ConclusionsAccording to the results, total direct medical costs for HCV patients in Iran exceeded 12 billion PPP$ in (INF-RBV) treatment and 55 billion PPP$ in (PEG-RBV).

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

et al. 2013

View full text Add to dashboard Cite

show abstract

“…But there is a difference between developed and undeveloped countries in its prevalence. It is due to difference in health policies and medical care [10]. Apart from few studies that have been done on high-risk groups or in specific locations, no comprehensive and accurate estimate of HCV infection is available in Iran.…”

Section: Introductionmentioning

confidence: 99%

“…The occurrence of end-stage liver disease caused by HCV is estimated to peak around 2020 [10, 14]. According to other studies, HCV infection is responsible for 20% of acute hepatitis cases, 70% of all chronic hepatitis cases, 40% of all cases of liver cirrhosis, 60% of hepatocellular carcinomas (HCC), and 30% of liver transplants [15].…”

Section: Introductionmentioning

confidence: 99%

Application of Zero-Inflated Poisson Mixed Models in Prognostic Factors of Hepatitis C

Baghban

Pourhoseingholi

Zayeri

et al. 2013

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background and Objectives. In recent years, hepatitis C virus (HCV) infection represents a major public health problem. Evaluation of risk factors is one of the solutions which help protect people from the infection. This study aims to employ zero-inflated Poisson mixed models to evaluate prognostic factors of hepatitis C. Methods. The data was collected from a longitudinal study during 2005–2010. First, mixed Poisson regression (PR) model was fitted to the data. Then, a mixed zero-inflated Poisson model was fitted with compound Poisson random effects. For evaluating the performance of the proposed mixed model, standard errors of estimators were compared. Results. The results obtained from mixed PR showed that genotype 3 and treatment protocol were statistically significant. Results of zero-inflated Poisson mixed model showed that age, sex, genotypes 2 and 3, the treatment protocol, and having risk factors had significant effects on viral load of HCV patients. Of these two models, the estimators of zero-inflated Poisson mixed model had the minimum standard errors. Conclusions. The results showed that a mixed zero-inflated Poisson model was the almost best fit. The proposed model can capture serial dependence, additional overdispersion, and excess zeros in the longitudinal count data.

show abstract

“…However, considering the cost and availability issue of such treatment regimens, local recommendations would assist clinicians with their decision-making in this regard. The recommendations laid down by the experts panel during the scientific leaders’ meeting, July 2011, Tehran ( 13 ), re-emphasized the significance of evidence-based decisions for using any new HCV therapy regimen in Iran; whereby, cost-benefit analysis should be carefully considered before decision making.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013

et al. 2013

Self Cite

View full text Add to dashboard Cite

The cross-border symposium on hepatitis C, entitled “why treating now?” was held on 15th May 2013 during the 5th International Tehran Hepatitis Congress. The present report summarizing communicated insights during this symposium is intended to help health care providers to make well-informed decisions when treating patients with chronic hepatitis C (CHC). Since today’s evolving science of hepatitis C management has introduced new treatment options, one should be well-versed about the potential benefits as well as untoward effects or practical challenges when using these regimens. In addition to outline HCV treatment advances, this symposium focused on the central question that why eligible patients with hepatitis C who may mostly benefit from the currently available protease inhibitors, should be treated now rather than be waited for the future therapies. Moreover, an overview of long term local experience with protease inhibitors in our challenging hepatitis C patients was presented during this interactive symposium.

show abstract

Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran

Cited by 5 publications

References 4 publications

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Application of Zero-Inflated Poisson Mixed Models in Prognostic Factors of Hepatitis C

Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013

Contact Info

Product

Resources

About